Transgene Awarded EUR 1.3 M Grant for Hepatitis C Therapeutic Vaccine Programme
The grant aims at strengthening the development of Transgene's vaccine candidate TG4040 (MVA-HCV). TG4040 is currently undergoing preclinical studies and should enter Phase I/II trial by mid-2006 to treat patients not responding to standard therapy. The TG4040 development programme is carried out by Transgene's infectious diseases research team based in Lyon, France. Research units of INSERM, CNRS, Grenoble University Hospital and Lyon Civil Hospitals will also participate in the subsidised programme.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.